Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 10Phase 1 10Phase 1/2 6Phase 4 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma 25Leukemia 20Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Non-Hodgkin 15Lymphoma, Follicular 15Neoplasms 14Recurrence 10Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 10Hematologic Neoplasms 8Burkitt Lymphoma 8Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Hodgkin Disease 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Plasma Cell 5Neoplasms by Site 5Neoplasms by Histologic Type 5Multiple Myeloma 5Lymphoproliferative Disorders 5Lymphoma, Mantle-Cell 5Infections 5Graft vs Host Disease 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Leukemia, Biphenotypic, Acute 4Anemia, Refractory, with Excess of Blasts 4Lymphoma, T-Cell, Peripheral 3Leukemia, T-Cell 3

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Bronchiolitis Obliterans Syndrome × Lymphoid × Clear all
NCT00349518 2016-02-17

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Bristol-Myers Squibb

Phase 2/3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡